For the Inventor, By the Inventor

Enter assignee name

Boston, MA, United States of America

Paratek Pharmaceuticals, Inc.

USPTO Granted Patents = 71

% Expired Patents = 59.2

CIPO Patents = 2

EPO Patents = 23

Trademarks = 9

Forward Citations = 880

Loading Chart...

Loading Chart...

62 inventors (with patents filed for the assignee):

Mark L Nelson (38 out of 70 patents)

Roger Frechette (21 out of 24 patents)

Beena Bhatia (16 out of 18 patents)

4. Todd Bowser (15 out of 16 patents)

5. Mohamed Y Ismail (15 out of 19 patents)

6. Tadeusz Warchol (13 out of 13 patents)

7. Michael P Draper (12 out of 13 patents)

8. Laura Honeyman (10 out of 10 patents)

9. S Ken Tanaka (9 out of 11 patents)

10. Peter Viski (9 out of 10 patents)

11. Jose Maria Fiandor (9 out of 11 patents)

12. Stuart B Levy (8 out of 34 patents)

13. Laura McIntyre (8 out of 9 patents)

14. Sean M Johnston (7 out of 10 patents)

15. Joel Berniac (7 out of 7 patents)

Core Competencies:

Tetracycline Compounds

Minocycline

Community-Acquired Pneumonia

Urinary Tract Infection

Biodefense

Inflammatory Skin Disorders

Antifungal Agents

Bioavailability

RNA Modulation

Spinal Muscular Atrophy

Polypeptide Binding

Synthesis Methods

71 patents: Sort by Forward Citations

1. 12161655 - Methods of treating mycobacterial infections using tetracycline compounds (2024-12-10),

2. 11129839 - Minocycline compounds for biodefense (2021-09-28),

3. 10835542 - 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) (2020-11-17),

4. 10383884 - 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) (2019-08-20),

5. 10238670 - 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (UTI) treatment (2019-03-26),

6. 10124014 - Minocycline compounds and methods of use thereof (2018-11-13),

7. 10111890 - 9-aminomethyl minocycline compounds and uses thereof (2018-10-30),

8. 9724358 - Minocycline compounds and methods of use thereof (2017-08-08),

9. 9562003 - Methods of using substituted tetracycline compounds to modulate RNA (2017-02-07),

10. 9533943 - Substituted tetracycline compounds (2017-01-03),

11. 9522872 - Methods for synthesizing substituted tetracycline compounds (2016-12-20),

12. 9481639 - Substituted tetracycline compounds for treatment of inflammatory skin disorders (2016-11-01),

13. 9434680 - Methods for synthesizing and purifying aminoalkyl tetracycline compounds (2016-09-06),

14. 9365500 - 9-aminomethyl substituted minocycline compounds (2016-06-14),

15. 9314475 - Oral and injectable formulations of tetracycline compounds (2016-04-19),

Company Overview

Paratek Pharmaceuticals, Inc. is a Boston-based biopharmaceutical company focused on developing innovative therapies utilizing tetracycline compounds. The company specializes in addressing serious infections, particularly those caused by resistant bacteria, and has a strong emphasis on conditions such as community-acquired pneumonia and urinary tract infections. Paratek also explores applications in biodefense and inflammatory skin disorders, enhancing the bioavailability of its therapeutic agents to improve patient outcomes.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

71 Patents

#37 in Boston, MA

#289 in Massachusetts

#5,162 in US

#10,503 in the World

Boston, MA, United States of America

Paratek Pharmaceuticals, Inc.

Forward Citations = 880

62 inventors:

Mark L Nelson (38 out of 70 patents)

Roger Frechette (21 out of 24 patents)

Beena Bhatia (16 out of 18 patents)

4. Todd Bowser (15 out of 16 patents)

5. Mohamed Y Ismail (15 out of 19 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Paratek Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/paratek-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…